SequelSEC

DEXCOM INC DXCM

Surgical & Medical Instruments & Apparatus · CIK 0001093557 · Fiscal year ends 1231

Revenue
$4.97B
Fiscal year ended 2026-06-30
Operating income
$1.14B
Fiscal year ended 2026-06-30
Free cash flow
$1.40B
Fiscal year ended 2026-06-30

DEXCOM INC (DXCM) reported revenue of $4.97B and net income of $999.70M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from DEXCOM INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

DEXCOM INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$4.97B
Cost of revenue$1.86B
Gross profit$3.10B
Operating income$1.14B
Net income$999.70M
Research & development$604.00M
Weighted-average diluted sharesUnavailable
Pretax income$1.28B
Income tax expense$280.30M
Diluted EPSUnavailable
Selling, general & administrative$1.36B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

DEXCOM INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.10B
Total assets$6.46B
Current assets$4.09B
Total liabilities$3.83B
Current liabilities$2.36B
Total equity incl. NCI$2.62B
Temporary (mezzanine) equityUnavailable
Inventory$726.40M
Accounts receivable$1.26B
Goodwill$24.10M
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

DEXCOM INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$1.75B
Capital expenditures$343.70M
Investing cash flow$530.70M
Financing cash flow-$2.33B
Net change in cash-$55.10M
Stock-based compensation$162.40M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$210.30M

Derived

DEXCOM INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$1.40B
Gross margin62.5%
Operating margin22.9%
FCF margin28.3%
SBC / revenue3.3%
Current ratio1.73x
Revenue YoY growth15.5%
Net margin20.1%
R&D / revenue12.2%
CapEx / revenue6.9%
Long-term debt / equityUnavailable
Effective tax rate21.9%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DXCM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.